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Abstract 
Background and Purpose: The optimal timing for starting oral anticoagulant after an ischemic 
stroke related to atrial fibrillation (AF) remains a challenge, mainly in patients treated with systemic 
thrombolysis or mechanical thrombectomy. We aimed at assessing the incidence of early recurrence 
and major bleeding in patients with acute ischemic stroke and AF treated with thrombolytic therapy 
and/or thrombectomy, who then received oral anticoagulants for secondary prevention.  
Methods: We combined the dataset of the RAF and the RAF-NOACs studies, which were 
prospective observational studies carried out from January 2012 to March 2014 and April 2014 to 
June 2016, respectively. We included consecutive patients with acute ischemic stroke and AF 
treated with either vitamin K antagonists or non-vitamin K oral anticoagulants. Primary outcome 
was the composite of stroke, transient ischemic attack, symptomatic systemic embolism, 
symptomatic cerebral bleeding and major extracerebral bleeding within 90 days from the inclusion. 
Treated-patients were propensity matched to untreated-patients in a 1:1 ratio after stratification by 
baseline clinical features. 
Results: A total of 2,159 patients were included, 564 (26%) patients received acute reperfusion 
therapies. After the index event, 505 (90%) patients treated with acute reperfusion therapies and 
1,287 of 1,595 (81%) patients untreated started oral anticoagulation. Timing of starting oral 
anticoagulant was similar in reperfusion-treated and untreated patients (median 7.5 vs 7.0 days, 
respectively). At 90 days, the primary study outcome occurred in 37 (7%) patients treated with 
reperfusion and in 146 (9%) untreated patients (OR 0.74; 95% CI 0.50-1.07). After propensity score 
matching, risk of primary outcome was comparable between the two groups (OR 1.06; 95% CI 
0.53-2.02). 
Conclusions: Acute reperfusion treatment did not influence the risk of early recurrence and major 
bleeding in patients with AF-related acute ischemic stroke, who started on oral anticoagulant. 
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Introduction 
The optimal starting time of anticoagulant treatment after an acute ischemic stroke in patients with 
non-valvular atrial fibrillation (AF) remains highly debated. In these patients, current guidelines, 
which are mostly based on observational studies and consensus opinions, recommend using the 
lesion size and the stroke severity to decide when to start oral anticoagulant [1-3].  
 Due to paucity of data, urgent reperfusion therapies are not currently taken into account in 
the decision on whether and when oral anticoagulation should be initiated after AF-related acute 
ischemic stroke. Acute reperfusion treatments by systemic thrombolysis and/or mechanical 
thrombectomy are associated with a better outcome, yet with a non-negligible risk of hemorrhagic 
transformation [4-5]. Antithrombotic therapy within the first 24 hours after systemic thrombolysis 
(with or without mechanical thrombectomy) is not currently recommended [2], and, after this time 
interval, the optimal timing of starting oral anticoagulant treatment remains to be defined. In small 
observational studies, early introduction of non-vitamin K oral anticoagulant (NOACs) in patients 
with acute stroke appeared to be safe in patients treated with acute reperfusion therapy [6-8]. 
We aimed at assessing the incidence of early recurrence and major bleeding in patients with 
acute ischemic stroke and AF treated with thrombolytic therapy and/or thrombectomy, who then 
received oral anticoagulants for secondary prevention. 
 
Methods 
The data that support the findings of this study are available from the corresponding author upon 
reasonable request. We pooled the datasets of the RAF and the RAF-NOACs studies, which were 
prospective observational studies carried out from January 2012 to March 2014 and April 2014 to 
June 2016, respectively. Both studies enrolled consecutive patients with acute ischemic stroke and 
known or newly diagnosed AF without permanent contraindications to oral anticoagulant. The RAF 
study included patients treated with either vitamin K antagonists (VKAs) or NOACs, and the RAF-
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NOACs study only patients treated with NOACs. The design and methods of the two studies have 
been previously described [9,10].  
For the purpose of this analysis, we compared clinical features and outcomes of patients 
treated and untreated with acute reperfusion treatment. Acute reperfusion therapies included 
systemic thrombolysis (intravenous rt-PA) and/or intra-arterial thrombectomy that were delivered as 
per standard local protocol as considered appropriate by local investigators. Standard stroke unit 
care, monitoring, and treatment were provided according to current international recommendations 
for acute ischemic stroke. Attending physicians made decisions regarding the type of anticoagulant 
to be prescribed for secondary stroke prevention, as well as the day of initiation of anticoagulant 
treatment. Types of anticoagulant prescribed for secondary stroke prevention were: i) VKAs alone 
or with bridging therapy with low-molecular weight-heparin (LMWH), ii) NOACs alone or with 
bridging therapy with LMWH, iii) LMWH alone or iv) no anticoagulant treatment. Bridging 
therapy with LMWH was defined as any temporary full dose of LMWH (eg, 100 UI/kg of 
enoxaparin twice a day) started before or with VKAs, to cover the time needed by these last agents 
to reach the therapeutic effect or as any full dose (given for at least 24 hours) of LMWH before the 
use of a NOAC [11]. Follow-up visits or telephone contacts were prospectively performed.  
The study was approved by the local institutional review boards, if required. Informed 
consent was provided by study participants in countries where this was required by law. 
 
Outcomes 
The primary outcome was the composite of stroke, transient ischemic attack (TIA), symptomatic 
systemic embolism, symptomatic cerebral bleeding, and major extracerebral bleeding within 90 
days from the inclusion in the study [9,10]. Secondary outcomes were: i) any ischemic event; ii) any 
hemorrhagic event; iii) all-cause death and iv) disability using the modified Rankin Scale. Ischemic 
events included ischemic stroke, TIA, and symptomatic systemic embolism. Symptomatic cerebral 
bleeding and major extracerebral bleeding were considered as hemorrhagic events. 
	 7	
Stroke was defined as an acute episode of focal neurological deficit of vascular origin in a 
site consistent with the territory of a major cerebral artery and categorized as ischemic or 
hemorrhagic. TIA was defined as a transient episode of neurological dysfunction caused by focal 
brain ischemia without acute infarction. Systemic embolism was defined as an acute vascular 
occlusion of an extremity or organ confirmed by imaging, surgery, or autopsy. Cerebral bleeding 
was considered symptomatic if associated with a decline in neurological status quantified as an 
increase of 4 points of the NIHSS or leading to death. Extra-cerebral major bleeding was defined 
according to the ISTH criteria, which consist of a reduction in the hemoglobin level by at least 2 
g/dL, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ or 
fatal bleeding [12]. All-cause death was defined as death from any cause during the study period. 
Disability was assessed using the modified Rankin scale. Disability functional outcome was defined 
as a modified Rankin scale score of 3 to 5. 
 
Statistical Analyses 
We compared baseline characteristics of reperfusion-treated and untreated patients using the χ2 test 
for categorical variables or the Mann-Whitney U test for continuous variables. Patient’s 
characteristics were summarized as mean ± standard deviation (SD) if normally distributed and as 
median and interquartile range (IQR) if not normally distributed for continuous variables and as 
absolute numbers and percentages for categorical variables.  
The risk of study outcomes between reperfusion-treated and untreated patients was 
compared using logistic regression analysis. Results were reported as odds ratios (ORs) and 95% 
confidence intervals (CI). A multivariable analysis was performed using logistic regression to 
determine independent predictors of the primary outcome, any ischemic event and any hemorrhagic 
event. The independent variables of interest included in the multivariable models were: permanent 
AF, current smoker, lesion size, type of reperfusion treatment, type of oral anticoagulant therapy 
and CHA2DS2-Vasc score.  
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The risk of study outcomes over time in reperfusion-treated and untreated patients was 
compared using Cox proportional hazards regression models. All associations were presented as 
hazard ratios (HRs) and corresponding 95% CIs. These analyses were adjusted for the following 
risk factors: permanent AF, current smoker, lesion size, oral anticoagulant type and CHA2DS2-Vasc 
score. Patients were censored at the time of an outcome event or death. A two-sided P<0.05 was 
considered significant.  
Furthermore, a propensity score matching was used to balance the differences in baseline 
characteristics between reperfusion-treated and untreated patients. The propensity scores for 
treatment status were estimated from a logistic regression model which included the following 
covariables: age, gender, NIHSS at admission, hypertension, diabetes, dyslipidemia, paroxysmal 
AF, current smoker, history of congestive heart failure, previous stroke or transient ischemic attack, 
the use of oral anticoagulant, the use of LMWH (with or without bridging). Patients treated with 
acute reperfusion therapies were matched to untreated patients in a 1:1 ratio. Standardized 
difference was used to assess the balance of covariates after matching, and a standardized difference 
<10% was considered acceptable [13-14]. Logistic regression analysis was used to compare primary 
and secondary outcomes in each propensity score–matched cohort. 
All statistical analyses were performed using the IBM SPSS Statistics version 23.0 (IBM 
Corporation, Armonk, NY). 
 
Results 
A total of 2,159 patients were included in the RAF and RAF-NOACs trials, of which 564 (26%) 
patients were treated with acute reperfusion therapy. Of these, 471 patients were treated with 
systemic thrombolysis and 57 patients with endovascular thrombectomy. The remaining 36 patients 
received both systemic thrombolysis and endovascular thrombectomy. The characteristics of the 
patients are summarized in Table 1. 
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Patient treated with acute reperfusion therapies were younger than untreated patients 
(74.5±10.1 vs 76.9±9.6, p <0.001) and had more often paroxysmal AF (p <0.001), history of 
diabetes (p <0.001), previous stroke (p <0.001) and a CHA2DS2-Vasc score equal or more than 5 (p 
<0.001). Neurological impairment assessed by NIHSS on admission, as well as the size of the 
lesion were significantly higher in patients treated with reperfusion than those untreated (both 
p<0.001). Before the acute stroke, 50 of 564 (8.9%) patients treated with urgent reperfusion and 487 
of 1,595 (30.5%) untreated patients were on oral anticoagulants  (Table I, online Supplement). 
After acute stroke, 1,792 patients received oral anticoagulant therapy, of which 505 of the 
564 (90%) patients who were initially treated with acute reperfusion therapies. Oral anticoagulants 
were commenced in 1,287 of 1,595 (81%) patients untreated with reperfusion (p=0.147). Timing of 
starting oral anticoagulant was similar in reperfusion-treated and untreated patients (median 7.5 
(IQR 10) Vs 7.0 (IQR 11) days respectively, p=0.287). NOACs were used in 76% of patients 
treated with reperfusion and in 65% of untreated patients (p <0.001) (Table 1). After acute stroke, 
bridging therapy with LMWH before anticoagulant treatment was used in 95 of 564 (17%) patients 
treated with reperfusion therapies and 277 of 1,595 (17%) patients non receiving reperfusion 
therapies, NOAC alone was started in 336 treated (60%) and in 770 (48%) untreated patients, while 
no anticoagulant treatment in 5% and 13% of patients, respectively. The type of anticoagulant 




At 90 days, the primary study outcome occurred in 37 (7%) patients treated with reperfusion 
treatment and in 146 (9%) untreated patients (OR 0.74; 95% CI 0.50-1.07) (Table 2). Risk of 
primary outcome was 1.23 (95% CI 0.52-2.92) in patients treated with intra-arterial thrombectomy 
and 0.68 (95% CI 0.46-1.02) in patients treated with both rt-PA and intra-arterial thrombectomy as 
compared to untreated patients. 
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Twenty-four (4%) patients in the treated group and 82 (5%) patients in the untreated group 
had an ischemic event (OR 0.82; 95% CI 0.51-1.31). No significant differences were observed as to 
symptomatic hemorrhagic intracerebral and extracerebral events between treated and untreated 
patients (2% vs 4%, respectively) (OR 0.56; 95% CI 0.31-1.03). Extracerebral hemorrhages 
occurred in 3 (0.5%) patients in the treated group and in 20 (1.2%) patients in the untreated group. 
Seven patients in the untreated group experienced both an ischemic and hemorrhagic event. 
Hemorrhagic transformation at 24-72 hours occurred in 63 (11%) patients treated with reperfusion 
therapies and in 176 (11%) untreated patients (OR 1.01; 95% CI 0.75-1.38) (Table 2).  
Compared with untreated patients, patients treated with reperfusion therapies had similar 
rates of all-cause death (4% vs 7%, OR 0.65; 95% CI 0.42-1.00) and disability (mRS 3-5) (32% vs 
31%, OR 1.07; 95% CI 0.87-1.31).  
By restricting the analysis to patients treated only with i.v. thrombolysis, we found that 
patients receiving i.v. thrombolysis had a significant lower risk of the primary outcome compared to 
untreated patients (OR 0.61; 95% CI 0.40-0.94) (Table III, Online Supplement).  
In the Cox regression analyses, the risk of primary outcome over time was similar in patients 
treated and not treated with reperfusion treatments (adjusted HR 0.90, 95% CI 0.55-1.47) (Figure 
1). No differences were observed in term of risk of an ischemic event (adjusted HR 0.89, 95% CI 




In the multivariable analysis, the presence of lesion larger than 1.5 centimeters in brain 
imaging (OR 1.84, 95% CI 1.2-2.7), and the CHA2DS2-Vasc score (OR for each increasing point 
1.24, 95% CI 1.06-1.43) resulted to be independent predictors of increased risk for the primary 
study outcome,. In contrast, the use of NOACs was associated with a significant reduced odd of the 
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primary outcome (OR 0.42, 95% CI 0.29-0.65) (Table 3). Acute reperfusion treatment was not 
associated with the primary outcome (OR 0.87, 95% CI 0.54-1.38).  
Factors associated with an ischemic event and with a hemorrhagic event are shown in Table 
3. The use of NOACs was independently associated with lower risk of an ischemic event (OR 0.38, 
95% CI 0.24-0.66) and of a hemorrhagic event (OR 0.55, 95% CI 0.28-0.94). 
 
Propensity Score–Matched Cohort 
After propensity score 1:1 matching, 304 patient-pairs were formed. No differences were observed 
in patients treated with and without acute reperfusion therapies after matching (Table 4). In the 
matched populations, the risk of the primary outcome was comparable between reperfusion-treated 
and untreated patients (OR 1.06; 95% CI 0.53-2.02) (Table 5). No differences were observed in the 




Our study showed that the rates of acute ischemic stroke patients with AF who initiated oral 
anticoagulation was similar in subjects receiving or not receiving acute reperfusion therapies, while 
the median elapsed time interval from the index event was 7 days. At 90 days, patients treated with 
or without reperfusion had a similar risk of the composite outcome as well as of any ischemic or 
hemorrhagic event. The use of NOACs was associated with an improved efficacy and safety profile 
compared to VKAs both for ischemic and hemorrhagic outcomes.  
Our study is a prospective observational study that enrolled 2,159 patients of which 564 
were treated with reperfusion strategy. We observed that patients treated with acute reperfusion 
therapies had higher baseline NIHSS and lower lesion volume and comorbidities compared to 
untreated patients. However, to overcome these different patient’s features among the two study 
groups, we performed a propensity score matching. We found that the similar risk of primary 
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outcome observed in the treated and untreated population was independent of the influence of co-
morbidity, as shown by its persistence after adjustment for baseline features according to a 
propensity score matching 1:1. Interestingly, when we included in the analysis only patients treated 
with i.v. thrombolysis alone, these patients had a significant lower risk of primary outcome than 
patients	non receiving reperfusion therapy. In this view, we believe that starting early anticoagulant 
treatment after acute stroke in these patients would be a reasonable option.  
Our study provides novel observation about the start of anticoagulation in these patients and 
confirms previous findings of smaller studies as shown by a recent review [15]. The early 
introduction (within the first two weeks) of rivaroxaban or dabigatran in thirty-four patients with 
AF-related ischemic stroke treated with intravenous rt-PA appeared to be safe [6]. None of these 
patients experienced symptomatic hemorrhagic transformation or a symptomatic recurrent ischemic 
event. Reassurance regarding the early initiation of rivaroxaban in patients with AF-associated 
minor ischemic stroke was also shown in a small randomized-controlled clinical trial from Korea 
[16]. Similarly, in a retrospective study of 35 stroke patients treated with urgent reperfusion, 
NOACs were started within a median of 6 days after stroke. At 90 days, one patient had a 
symptomatic cerebral hemorrhage [7]. Moreover, in a prospective cohort of 73 patients with 
ischemic stroke receiving thrombolysis, early initiation of NOACs (within 2-4 days) after 
thrombolytic therapy appeared to be associated with lower risk of hemorrhagic events compared to 
VKAs. However, there was no significant difference (0 vs. 5.6 %, p= 0.240) due to the limited 
number of the included patients [8]. Preventing stroke and avoiding hemorrhagic transformation 
represents the cornerstone of secondary prevention in non-valvular AF-related acute ischemic 
stroke, and reperfusion treatment is usually considered to increase the risk of hemorrhagic 
complications in the early phase of stroke. Our study suggests that reperfusion treatment does not 
influence the clinical outcomes of patients with AF-related acute ischemic stroke, since acute 
reperfusion therapies did not emerge as independent predictors of any ischemic and/or hemorrhagic 
outcome. Interestingly, in our study the presence of a small lesion in brain imaging and high 
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CHA2DS2-Vasc score were inversely correlated to the primary outcome. Therefore, we believe that 
patients with a high CHA2DS2-VASc score and a small lesion size could safely start early 
anticoagulant treatment with NOACs, particularly if they were treated with thrombolytic treatment. 
Moreover, we found that the use of NOAC alone without bridging therapy with LMWH was 
the best treatment option in these patients. None of the NOAC phase III randomized-controlled 
clinical trials included patients who had experienced a recent ischemic stroke (within the first 
weeks) [17-20]. However, in a meta-analysis of these clinical trials of AF patients with previous 
TIA or stroke, NOACs were associated with a significant reduction of stroke, stroke or systemic 
embolism, hemorrhagic stroke, and intracranial bleeding compared to VKAs [21]. Our results 
expand previous findings confirming the highest safety and efficacy profile of NOACs over VKAs 
even in patients with AF-related acute ischemic stroke treated with urgent reperfusion therapy, 
supporting the observations of other datasets [22-23]. 
Our study had several limitations. First, this was not a randomized study and therefore the 
results were possibly influenced by some confounders. Indeed, the different time periods of data 
collection, the non randomized selection of the individual anticoagulant treatment and their doses 
could have influenced our results. However, the study has the advantage to reflect the changes and 
the real-life experiences in clinical practice in this clinical setting. Second, the number of study 
outcome events was relatively low, leading to a reduction of statistical power of the study. In this 
view, the results of sub-group analyses should be regarded with caution. Third, the possibility of 
selection bias regarding the starting time of anticoagulant therapy cannot be excluded. Fourth, the 
number of patients who were treated with endovascular reperfusion therapies was limited (<100 
cases) and this needs to be taken into account when interpreting our findings.  
 
Conclusions 
In conclusion, our study suggests that acute reperfusion therapies appear not to influence the risk of 
early recurrence and major bleeding in patients with AF-related acute ischemic stroke, who 
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subsequently started oral anticoagulant treatment. Therefore, acute reperfusion treatment should not 
refrain stroke physicians from an early initiation of oral anticoagulation for secondary stroke 
prevention when the potential benefits outweigh the perceived risks. Further studies, preferably 
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Demographics     
Age  74.54±10.1 76.96±9.6 <0.001 
Female 260 (46%) 735 (46%) 0.961 
Risk factors    
Diabetes 94 (17%) 388 (24%) <0.001 
Hypertension 431 (77%) 1258 (79%) 0.171 
Hyperlipidemia 184 (33%) 540 (34%) 0.640 
Paroxysmal AF 284 (50%) 646 (41%) <0.001 
Previous stroke 104 (19%) 464 (29%) 0.001 
Current Smoking 50 (9%) 156 (10%) 0.560 
Alcoholism 30 (5%) 112 (7%) 0.198 
Chronic heart failure 84 (15%) 285 (18%) 0.118 
Previous MI 68 (12%) 231 (15%) 0.157 
Peripheral arterial disease 39 (7%) 143 (9%) 0.135 
Aortic atheroma 44 (8%) 123 (8%) 0.711 
Pacemaker 36 (6%) 114 (7%) 0.630 
CHA2DS2-VASc ≥5 406 (72%) 1264 (79%) 0.0001 
Clinical and radiological characteristics   
Lesion <1.5cm 154 (27%) 666 (42%) <0.001 
NIHSS at admission, median (IQR) 10.0 (10) 4.0 (7) <0.001 
Treatment    
Resumption of oral anticoagulation 505 (90%) 1287 (81%) 0.147 
NOAC 384 (76%) 841 (65%) <0.001 
Warfarin 121 (22%) 446 (28%) <0.001 
Starting anticoagulation time (days), 
median (IQR) 7.5 (10) 7 (11) 0.287 
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Odds Ratio  
(95% CI) 
Primary outcome    
Any ischemic and any 
hemorrhagic event 
37 (7%) 139 (9%) Unadjusted OR 0.74; 95% CI 0.50-1.07 
Adjusted OR 0.85; 95% CI 0.53-1.36   
Secondary outcomes    
Any ischemic event 24 (4%) 82 (5%) Unadjusted OR 0.82; 95% CI 0.51-1.31 
Adjusted OR 1.01; 95% CI 0.56-1.72 
 
Any hemorrhagic event 13 (2%) 64 (4%) Unadjusted OR 0.56; 95% CI 0.31-1.03 
Adjusted OR 0.60; 95% CI 0.29-1.26 
 
Mortality 26 (4%) 111 (7%) Unadjusted OR 0.65; 95% CI 0.42-1.00  
Adjusted OR 0.47; 95% CI 0.29-0.78 
 
Disability (mRS 3-5) 182 (32%) 492 (31%) Unadjusted OR 1.07; 95% CI 0.87-1.31 
 
HT 24-72 63 (11.2%) 176 (11%) Unadjusted OR 1.01; 95% CI 0.75-1.38 
 OR 95% CI P 
Primary outcome 
Paroxysmal AF 0.77 0.51-1.11 0.212 
Lesion <1.5 cm 0.57 0.37-0.87 0.008 
Current smoker 0.74 0.33-1.64 0.454 
RTPA/IA 0.87 0.55-1.38 0.556 
CHA2DS2-VASc 1.24 1.06-1.44 0.006 
NOACs vs VKAs  0.44 0.29-0.65 <0.001 
Any ischemic event    
Paroxysmal AF 0.66 0.39-1.12 0.125 
Lesion <1.5 cm 0.70 0.49-2.85 0.183 
Current smoker 0.72 0.33-1.64 0.454 
RTPA/IA 0.98 0.55-1.76 0.961 
CHA2DS2-VASc 1.29 1.07-1.56 0.008 
NOACs vs VKAs 0.40 0.24-0.66 <0.001 
Any hemorrhagic event    
Paroxysmal AF 0.97 0.53-1.78 0.922 
Lesion <1.5 cm 0.43 0.22-0.84 0.013 
Current smoker 0.21 0.03-1.54 0.125 
RTPA/IA 0.67 0.32-1.38 0.274 
CHA2DS2-VASc 1.11 0.88-1.39 0.379 
NOACs vs VKAs 0.52 0.29-0.95 0.033 
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Multivariate analysis of the primary outcome and of any ischemic and any hemorrhagic event
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Age (years, mean) 75.6±9.4 75.1±9.7 0.5 
Female sex 165 (54.3%) 157 (51.6%) 0.6 
NIHSS at admission (mean) 8.9±5.0 8.3±6.9 0.2 
Diabetes Mellitus 65 (21.4%) 53 (17.4%) 0.3 
Hypertension 235 (77.3%) 234 (77.0%) 1.0 
Dyslipidemia 96 (31.6%) 96 (31.6%) 1.0 
Paroxysmal AF 146 (48.0%) 147 (48.4%) 1.0 
Current smoker 26 (8.6%) 27 (8.9%) 1.0 
History of stroke/TIA 76 (25.0%) 65 (21.4%) 0.3 
History of CHF 45 (14.8%) 54 (17.8%) 0.4 
Use of oral anticoagulant 











Table 5. Risks of primary and secondary outcome after propensity score matching between patients 









Odds Ratio  
(95% CI) 
   P 
Primary outcome 20 (6.6%) 19 (6.3%) 1.06 (95% CI 0.53-2.02) 0.9 
Any ischemic event 13 (4.3%) 11 (3.6%) 1.19 (95% CI 0.52-2.70) 0.7 
Any hemorrhagic event 7 (2.3%) 10 (3.3%) 0.69 (95% CI 0.26-1.84) 
 
0.6 
 
 
